RBC Says Vertex Stock May Appreciate Further on Povetacicept Approval and Launch
RBC said Vertex Pharmaceuticals stock may see further appreciation following approval and launch of povetacicept.
Related stories
U.S. Stocks Extend Gains; S&P 500 Up 0.70%, Nasdaq Up 1.2%
M impact | EQUITY | Nov 03, 2026, 06:35 PM UTC
ICAPE Reports Q3 2026 Revenue of €68.7 Million
M impact | EQUITY | Nov 03, 2026, 06:33 PM UTC
Herbalife Publishes Q3 2026 Earnings Call Transcript
The transcript notes that Herbalife raised its 2026 reported sales guidance; the provided text is truncated.
M impact | EQUITY | Nov 03, 2026, 06:32 PM UTC
Barclays Runs Sale Process for Exeter Finance’s Nonprime Auto Loans
Barclays is running a sale process for up to $1 billion of Exeter Finance’s nonprime auto loans.
M impact | EQUITY | Nov 03, 2026, 06:30 PM UTC
US session market picture: S&P 500 +0.53%, Nasdaq 100 +0.87%; EUR/USD +0.09%, WTI -0.43%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.53 percent, Nasdaq futures is up 0.87 percent, Dow futures is down 0.27 percent and Russell futures is up 0.69
M impact | EQUITY | Nov 03, 2026, 06:30 PM UTC
American Honda Sales Rise 8% in October
Honda Motor's American Honda unit reported an 8% sales rise in October.
L impact | EQUITY | Nov 03, 2026, 06:29 PM UTC